{"id":802568,"date":"2025-01-21T08:07:19","date_gmt":"2025-01-21T13:07:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/"},"modified":"2025-01-21T08:07:19","modified_gmt":"2025-01-21T13:07:19","slug":"lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/","title":{"rendered":"Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain"},"content":{"rendered":"<h2>\nEvent will feature insights on LX9211, Lexicon\u2019s novel, investigational, non-opioid treatment, as well as expert panel and Q&amp;A session on DPNP<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">THE WOODLANDS, Texas, Jan.  21, 2025  (GLOBE NEWSWIRE) &#8212; Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: \u201cLX9211 &#8211; Changing the Paradigm for Treatment of Neuropathic Pain.\u201d The event will be held from 9:00 a.m. to 11:00 a.m. ET on January 28, 2025.<\/p>\n<p>In advance of topline data from the Phase 2b PROGRESS trial anticipated later this quarter, the event will offer an in-depth overview on LX9211 for the treatment of diabetic peripheral neuropathic pain (DPNP), featuring remarks from Lexicon leaders including:<\/p>\n<ul type=\"disc\">\n<li>Mike Exton, PhD, Chief Executive Officer and Director<\/li>\n<li>Suma Gopinathan, PhD, Vice President, Clinical Development<\/li>\n<li>Craig Granowitz, MD, PhD, Senior Vice President and Chief Medical Officer<\/li>\n<\/ul>\n<p>In addition to presentations by the Lexicon leadership team, the event will include an expert panel and Q&amp;A session on DPNP featuring:<\/p>\n<ul type=\"disc\">\n<li>Rodica Pop-Busui MD, PhD, Jordan Schnitzer Chair in Diabetes | Professor of Medicine and Division Head, Endocrinology, Diabetes and Clinical Nutrition Director, Harold Schnitzer Diabetes Center, Oregon Health &amp; Science University | 2023 President for Medicine and Science, American Diabetes Association<\/li>\n<li>Steve Edelman, MD, Professor of Medicine, the Division of Endocrinology, Diabetes &amp; Metabolism at University of California San Diego | Veterans Affairs Medical Center | Founder and Director Taking Control Of Your Diabetes (TCOYD)<\/li>\n<\/ul>\n<p>Register for the event <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5VulWqllfcLwEqargvDoWOpYzTDqNodkPTkbWUWZEK2zpvW4K95Z1H8XkWe5w6ZS57QVaGCeZkGDZwsE9AAlXQqKdlWcMJjIwrUgalaDrD5_HK0SPrEXnjXi-OXBQ317\" rel=\"nofollow\" target=\"_blank\">here<\/a>.\u00a0The webcast will be available in the \u201cEvents\u201d section of the Lexicon website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fyWYVI6WDrqX3gbrJyRHjkRIk1fWVBXcEUAjUadH2-0hvkWfRE-UUM8eevCH2hE9p1LBJsnhQKO34vBlg6_QhfJN6RNiKuHfE1jLd_svejRVXI0C6_7oyUbcF3BO6pyA6XbyrMSf9XmWUAQXFuYbpDIqe-WSsmHktFNZMMLSMXM=\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.lexpharma.com\/news-events\/events<\/a> and a recording of the webcast will be available following the original on-demand date.<\/p>\n<p>\n        <strong>About Lexicon Pharmaceuticals <\/strong><br \/>\n        <br \/>Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients\u2019 lives. Through the Genome5000\u2122 program, Lexicon\u2019s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in cardiology, neuropathic pain, metabolism and other indications. For additional information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IQIzVi5G4clnnK5PjhV_R-cgZHpK4UXWGWa13IY5kWWQFTJt-KYRBsLVJOuS3-XXh8pT2f_oQuVS0Nt9WLlrLhgsP-FNCGTSjpfUvde1-g0=\" rel=\"nofollow\" target=\"_blank\">www.lexpharma.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>For Investor and Media Inquiries<\/strong>:<br \/>Lisa DeFrancesco <br \/>Lexicon Pharmaceuticals, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G-kuaNt98PyfrNUg1T8v88KLxP_p_qW_llswOx5Ud6zv5vsHLaPKUarmrR-YwEtR_88GPz9sZI6v7Xvf2GbujXgtPC_wchaWQClzEbCij68=\" rel=\"nofollow\" target=\"_blank\">lexinvest@lexpharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDQ5OSM2NzAwMDM5IzIwMDM5Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTdkOWU4ZDUtZWQ4Yy00MTlhLWI0MjYtNzI1YmZmNzlhOWRkLTEwMTU1NDA=\/tiny\/Lexicon-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Event will feature insights on LX9211, Lexicon\u2019s novel, investigational, non-opioid treatment, as well as expert panel and Q&amp;A session on DPNP THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) &#8212; Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: \u201cLX9211 &#8211; Changing the Paradigm for Treatment of Neuropathic Pain.\u201d The event will be held from 9:00 a.m. to 11:00 a.m. ET on January 28, 2025. In advance of topline data from the Phase 2b PROGRESS trial anticipated later this quarter, the event will offer an in-depth overview on LX9211 for the treatment of diabetic peripheral neuropathic pain (DPNP), featuring remarks from Lexicon leaders including: Mike Exton, PhD, Chief Executive Officer and Director Suma Gopinathan, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-802568","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Event will feature insights on LX9211, Lexicon\u2019s novel, investigational, non-opioid treatment, as well as expert panel and Q&amp;A session on DPNP THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) &#8212; Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: \u201cLX9211 &#8211; Changing the Paradigm for Treatment of Neuropathic Pain.\u201d The event will be held from 9:00 a.m. to 11:00 a.m. ET on January 28, 2025. In advance of topline data from the Phase 2b PROGRESS trial anticipated later this quarter, the event will offer an in-depth overview on LX9211 for the treatment of diabetic peripheral neuropathic pain (DPNP), featuring remarks from Lexicon leaders including: Mike Exton, PhD, Chief Executive Officer and Director Suma Gopinathan, &hellip; Continue reading &quot;Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-21T13:07:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDQ5OSM2NzAwMDM5IzIwMDM5Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain\",\"datePublished\":\"2025-01-21T13:07:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\\\/\"},\"wordCount\":400,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzNDQ5OSM2NzAwMDM5IzIwMDM5Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\\\/\",\"name\":\"Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzNDQ5OSM2NzAwMDM5IzIwMDM5Njc=\",\"datePublished\":\"2025-01-21T13:07:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzNDQ5OSM2NzAwMDM5IzIwMDM5Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzNDQ5OSM2NzAwMDM5IzIwMDM5Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/","og_locale":"en_US","og_type":"article","og_title":"Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - Market Newsdesk","og_description":"Event will feature insights on LX9211, Lexicon\u2019s novel, investigational, non-opioid treatment, as well as expert panel and Q&amp;A session on DPNP THE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) &#8212; Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company will host a virtual webcast: \u201cLX9211 &#8211; Changing the Paradigm for Treatment of Neuropathic Pain.\u201d The event will be held from 9:00 a.m. to 11:00 a.m. ET on January 28, 2025. In advance of topline data from the Phase 2b PROGRESS trial anticipated later this quarter, the event will offer an in-depth overview on LX9211 for the treatment of diabetic peripheral neuropathic pain (DPNP), featuring remarks from Lexicon leaders including: Mike Exton, PhD, Chief Executive Officer and Director Suma Gopinathan, &hellip; Continue reading \"Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-21T13:07:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDQ5OSM2NzAwMDM5IzIwMDM5Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain","datePublished":"2025-01-21T13:07:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/"},"wordCount":400,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDQ5OSM2NzAwMDM5IzIwMDM5Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/","name":"Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDQ5OSM2NzAwMDM5IzIwMDM5Njc=","datePublished":"2025-01-21T13:07:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDQ5OSM2NzAwMDM5IzIwMDM5Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDQ5OSM2NzAwMDM5IzIwMDM5Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lexicon-announces-virtual-webcast-on-lx9211-for-diabetic-peripheral-neuropathic-pain\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/802568","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=802568"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/802568\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=802568"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=802568"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=802568"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}